Clinical Trial

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, global, randomized, open-label, multicenter trial designed to evaluate the safety and efficacy of chronic treatment with brelovitug (BJT-778) for chronic hepatitis delta virus (HDV) infection. The objective of this study is to test the safety and effectiveness of brelovitug compared to delayed treatment.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-30
Trial Details
NCT Number NCT07298330
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions Chronic Hepatitis D Infection
Enrollment 80 participants
Start Date 2026-01-14
Primary Completion 2026-08 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-29